Vanda Pharmaceuticals Inc. (VNDA)

Market Cap	251.25M -3.4%
Revenue (ttm)	229.28M +8.1%
Net Income	-274.83M
EPS	-4.59
Shares Out	60.47M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	333,481
Open	4.155
Previous Close	4.080
Day's Range	4.060 - 4.184
52-Week Range	3.565 - 9.940
Beta	0.73
Analysts	Strong Buy
Price Target	11.50 (+176.78%)
Earnings Date	Oct 28, 2026

About VNDA

Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company’s commercial portfolio includes Fanapt for the acute treatment of manic or mixed episodes associated with bipolar I disorder and the treatment of schizophrenia; HETLIOZ to treat non-24-hour sleep-wake disorders and nighttime sleep disturbances; PONVORY to treat relapsing forms of multiple sclerosis; and NEREUSTM for preventing vomiting induced by motion. It also develop...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Apr 12, 2006
• Employees: 533
• Stock Exchange: Nasdaq
• Ticker Symbol: VNDA
• Website: https://www.vandapharma.com

Financial Performance

In 2025, Vanda Pharmaceuticals's revenue was $216.11 million, an increase of 8.72% compared to the previous year's $198.77 million. Losses were -$220.47 million, 1066.5% more than in 2024.

Analyst Summary

According to 5 analysts, the average rating for VNDA stock is "Strong Buy." The 12-month stock price target is $11.5, which is an increase of 176.78% from the latest price.

Price Target

$11.5

(176.78% upside)

Analyst Consensus: Strong Buy

Data Sources: S&P Global Market Intelligence, CBOE, and more

Fundamental and historical data is provided by S&P Global Market Intelligence. Real-time stock price data is provided by CBOE and 15-minute delayed consolidated tape pricing data is provided by Nasdaq UTP.

Last checked:

Nov 11, 2026

Data Sources Report a data error